Harmony Biosciences announced strong Q2 2026 earnings, beating revenue and EPS consensus, driven by significant WAKIX growth. The company also released positive Phase 1 data for BP-205, supporting its orexin development strategy and future Phase 2 studies, which could expand its neurology pipeline.
Harmony Biosciences reported record Q2 2026 revenue of $261.3 million, surpassing analyst estimates, and an EPS of $1.28, significantly beating the consensus. This strong financial performance was primarily driven by a 30% year-over-year growth in WAKIX net revenue. Additionally, the company announced favorable Phase 1 data for its investigational drug BP-205, which supports its broader orexin development strategy and plans for Phase 2 studies in multiple CNS indications starting mid-2027. This news is a significant positive catalyst for HRMY, indicating strong current product performance and promising future pipeline development, which could lead to sustained growth and increased market share in the neurology sector. Traders should note the stock's momentum building towards resistance, with potential for a breakout if positive sentiment continues.